EMBO Fellows meet in Heidelberg
Between 14 and 17 June 2018, 103 EMBO Long-Term Fellows came together for the annual Fellows’ Meeting in Heidelberg, Germany.
EMBO Short-Term Fellowships are now extendable
Following a change in eligibility criteria, EMBO Short-Term Fellows are now able to extend their research visits for a further 90 days to complete work on a collaborative project or further hone their newly acquired skills.
Open Science recommendations for the European Commission
“The European Union will not remain competitive at the global level unless it promotes Open Science, and relatedly, Open Innovation. The time is to act now.” This is how the Open Science Policy Platform (OSSP) introduces its recommendations for the European Commission that it published on 29 May 2018.
EMBO welcomes Montenegro as its 30th member
EMBO is pleased to announce that Montenegro has joined its intergovernmental funding body, the European Molecular Biology Conference (EMBC).
Three days of science and networking for Young Investigators
The annual Young Investigator Meeting took place from 16 to 18 May at the Vienna BioCenter in Austria.
EMBO Gold Medal 2018 awarded to Marek Basler and Melina Schuh
The recipients of the EMBO Gold Medal 2018 are Czech microbiologist Marek Basler and German biochemist Melina Schuh.
Illuminating the beginning of life
Melina Schuh, one of two recipients of the EMBO Gold Medal 2018, discusses how her love of microscopy and her drive to discover new things shapes her work on mammalian meiosis.
Tailoring blood cells in the laboratory
Researchers are a step closer to growing blood cells customized to the special needs of transfusion patients with rare blood groups
Preprint quality control
If we want to share results in a reproducible and discoverable manner, both quality control and curation should become part of the preprint process, argues EMBO Head of Scientific Publications, Bernd Pulverer.
How to hijack degrading complexes to put cancer cells asleep
Researchers uncover an alternative path of how the breast cancer drug palbociclib drives malignant cells into senescence